Impact of Hematopoietic Cell Transplantation on Myocardial Fibrosis in Young Patients with Sickle Cell Disease

Akshay Sharma; Subodh Selukar; Yu Bi; Anthony Merlocco; Cara Morin; Chris Goode; Parul Rai; Jeffrey Allen Towbin; Jane S Hankins; Stephen Gottschalk; Brandon M Triplett; Jason Nathaniel Johnson

doi:10.1182/blood.2023023028

Impact of Hematopoietic Cell Transplantation on Myocardial Fibrosis in Young Patients with Sickle Cell Disease

Blood. 2024 May 1:blood.2023023028. doi: 10.1182/blood.2023023028. Online ahead of print.

Affiliations

¹ St Jude Children's Research Hospital, Memphis, Tennessee, United States.
² St. Jude Children's Research Hospital, Memphis, Tennessee, United States.
³ University of Tennessee Health Science Center, Memphis, Tennessee, United States.
⁴ Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States.
⁵ The University of Tennessee Health Science Center, United States.

PMID: 38691679
DOI: 10.1182/blood.2023023028

Abstract

Serial cardiovascular magnetic resonance evaluation of children and young adults with sickle cell disease (SCD) who underwent hematopoietic cell transplantation (HCT) showed that the mean ECV, representing diffuse myocardial fibrosis, decreased by 3.4% from the baseline to 12-months post HCT. (NCT04362293).

Associated data

ClinicalTrials.gov/NCT04362293